BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HH160 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HH160\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07623369-2515@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:HH160: Phase 1 readout est. (NCT07623369)
DESCRIPTION:HH160\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A First-i
 n-Human Study of HH160 in Participants With Advanced or Metastatic Solid T
 umors\nEstimated primary completion: August 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/hh160#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07623369
URL:https://assetmemo.bio/drug/hh160#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
